全文获取类型
收费全文 | 4828篇 |
免费 | 465篇 |
国内免费 | 195篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 46篇 |
妇产科学 | 18篇 |
基础医学 | 265篇 |
口腔科学 | 47篇 |
临床医学 | 948篇 |
内科学 | 626篇 |
皮肤病学 | 12篇 |
神经病学 | 473篇 |
特种医学 | 66篇 |
外科学 | 182篇 |
综合类 | 462篇 |
一般理论 | 1篇 |
预防医学 | 768篇 |
眼科学 | 28篇 |
药学 | 888篇 |
6篇 | |
中国医学 | 551篇 |
肿瘤学 | 85篇 |
出版年
2024年 | 4篇 |
2023年 | 96篇 |
2022年 | 130篇 |
2021年 | 232篇 |
2020年 | 221篇 |
2019年 | 283篇 |
2018年 | 221篇 |
2017年 | 227篇 |
2016年 | 204篇 |
2015年 | 176篇 |
2014年 | 348篇 |
2013年 | 572篇 |
2012年 | 291篇 |
2011年 | 295篇 |
2010年 | 201篇 |
2009年 | 206篇 |
2008年 | 214篇 |
2007年 | 219篇 |
2006年 | 203篇 |
2005年 | 144篇 |
2004年 | 125篇 |
2003年 | 112篇 |
2002年 | 93篇 |
2001年 | 90篇 |
2000年 | 63篇 |
1999年 | 42篇 |
1998年 | 63篇 |
1997年 | 57篇 |
1996年 | 33篇 |
1995年 | 34篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 27篇 |
1991年 | 20篇 |
1990年 | 12篇 |
1989年 | 15篇 |
1988年 | 17篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 20篇 |
1984年 | 19篇 |
1983年 | 11篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 12篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 6篇 |
1974年 | 3篇 |
排序方式: 共有5488条查询结果,搜索用时 718 毫秒
1.
2.
3.
4.
《Sleep medicine》2021
BackgroundTheoretical models argue that coping reduces stress responses, yet no studies have tested whether coping moderates the prospective stress effects on sleep in daily life.PurposeThis study tested if coping moderates the stress-sleep association using a daily, intensive longitudinal design across 7–12 days.Methods326 young adults (Mage = 23.24 ± 5.46) reported perceived stress and coping (problem-focused, emotional-approach, and avoidance) every evening between 20:00–02:00, providing over 2400 nights of sleep data and 3000 stress surveys from all participants. Actigraphy and sleep diaries measured total-sleep-time and sleep efficiency. Multilevel models tested the interaction effects of within- and between-person stress and coping on sleep.ResultsWithin-person problem-focused and emotional-approach coping moderated the within-person stress effects on actigraphic total-sleep-time (both p = 0.02); higher stress predicted shorter total-sleep-time only during high use of problem-focused or emotional-approach coping (both p = 0.01). Between-person avoidance moderated the between-person stress effect on actigraphic total-sleep-time (p = 0.04); higher stress predicted shorter total-sleep-time for high avoidance coping (p = 0.02). Within-person emotional-approach coping buffered the between-person stress effect on actigraphic sleep efficiency (p = 0.02); higher stress predicted higher sleep efficiency for high emotional-approach coping (p = 0.04).ConclusionsThis study showed that daily coping moderates the effects of evening stress on sleep that night. More efforts to cope with stress before bedtime had a short-term cost of shorter sleep that night. However, high use of emotional-approach coping buffered the impact of stress to promote sleep efficiency. 相似文献
5.
6.
桃红四物汤,活血祛瘀之经典名方。该文对近年来桃红四物汤的化学成分、药理作用以及临床应用研究进展进行总结与分析。目前,桃红四物汤不同提取部位化学成分的研究较为系统,其药理作用研究主要集中在活血化瘀、调经镇痛、促进骨折愈合等方面,临床可应用于多系统、多脏腑疾病的治疗,例如妇科疾病、内科疾病、骨伤科疾病、皮肤科疾病等。在此基础上,依照质量标志物(Q-marker)有效、特有、传递与溯源、可测和处方配伍的"五原则"对桃红四物汤Q-marker进行预测分析,提示阿魏酸、芍药苷、苦杏仁苷、芍药内酯苷、梓醇、没食子酸、羟基红花黄色素A可作为该复方的Q-marker,后续可选择这些Q-marker为指标,根据药材、饮片、中间体、对应实物的量值传递进行桃红四物汤全程质量控制并创建其质量可溯源体系。 相似文献
7.
目的:建立大黄特征化学成分和抗氧化活性相关联的二维指纹图谱,研究大黄抗氧化活性物质。方法:利用高效液相多检测器联用的抗氧化活性成分在线检测体系,对大黄中化学成分进行检测,共鉴定出大黄中化学成分15种;其中8种具有抗氧化活性;然后采用清除效率为指标对各活性成分的抗氧化活性进行评价。结果:结果发现化合物葡萄糖紫丁香酸、腺嘌呤、没食子酸、儿茶素或表儿茶素、双花母草素、2-O-桂皮酰-没食子酰葡萄糖等具有较强的清除ABTS·+的活性,而蒽醌类成分对ABTS·+的清除作用较弱。结论:采用HPLC-ABTS-DAD-Q-TOF/MS对大黄中的抗氧化活性成分进行快速分析鉴定,初步阐明大黄在抗氧化环节起作用的效应物质。 相似文献
8.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献9.
10.